Payment overview · 2025
General Payments
$2,369.21
170 reported records · 17 companies
Healthcare provider profile · identity verified
Walter J Duffy, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · LINCOLN, NE · NPI 1093853368
Verified facts
What the public records show
CMS Open Payments records show Walter J Duffy, MD received $2,369.21 in general payments during 2025 across 170 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Aristada, Caplyta, Invega Sustenna, Lybalvi, Rexulti, Sunosi.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lybalvi by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Sunosi by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Invega Trinza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 87 records involving 83 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Abilify Maintena by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $445.18 | 18.8% | 26 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $342.20 | 14.4% | 15 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $302.76 | 12.8% | 34 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $297.77 | 12.6% | 30 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $290.61 | 12.3% | 18 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $218.78 | 9.2% | 23 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $82.31 | 3.5% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $70.90 | 3.0% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $63.77 | 2.7% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $57.87 | 2.4% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.27 | 2.2% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $40.41 | 1.7% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $31.15 | 1.3% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $22.85 | 1.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $22.22 | 0.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.61 | 0.6% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $13.55 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,269.22 | 169 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $445.18 | 26 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $342.20 | 15 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $302.76 | 34 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $302.76 | 34 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $218.78 | 23 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $208.97 | 22 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $146.00 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $144.61 | 9 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $88.80 | 8 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $82.31 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $70.90 | 4 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $63.77 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $57.87 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $52.27 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $40.41 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $31.15 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| REJOYN Normalized: rejoyn |
Device | Otsuka Pharmaceutical Development & Commercialization, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ARISTADA aristada |
2025 | Aristada | 2024 | 93 | exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 97 | exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 116 | exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
93 | 14 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
97 | 19 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
97 | 19 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
116 | 14 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA TRINZA open payments reported associated product |
CMS Open Payments — General Payments 8191 supporting records · 2146 recipient NPIs · example record 1174223262 |
Invega Trinza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 87 supporting records · 83 recipient NPIs · example record 1225319985 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Bupropion Xl | Bupropion Hcl | 525 | 69 |
| Lorazepam | Lorazepam | 492 | 70 |
| Quetiapine Fumarate | Quetiapine Fumarate | 451 | 67 |
| Alprazolam | Alprazolam | 442 | 77 |
| Lamotrigine | Lamotrigine | 420 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 419 | 71 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 387 | 53 |
| Buspirone Hcl | Buspirone Hcl | 383 | 72 |
| Trazodone Hcl | Trazodone Hcl | 319 | 64 |
| Clonazepam | Clonazepam | 318 | 58 |
| Aripiprazole | Aripiprazole | 301 | 57 |
| Mirtazapine | Mirtazapine | 272 | 64 |
| Olanzapine | Olanzapine | 265 | 31 |
| Methylphenidate Hcl | Methylphenidate Hcl | 260 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 250 | 43 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 246 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 228 | 37 |
| Divalproex Sodium Er | Divalproex Sodium | 216 | 29 |
| Risperidone | Risperidone | 206 | 26 |
| Vraylar | Cariprazine Hcl | 183 | 26 |
| Topiramate | Topiramate | 181 | 25 |
| Sertraline Hcl | Sertraline Hcl | 157 | 30 |
| Prazosin Hcl | Prazosin Hcl | 145 | 26 |
| Gabapentin | Gabapentin | 137 | 29 |
| Clozapine | Clozapine | 132 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 128 | 40 |
| Diazepam | Diazepam | 116 | 23 |
| Invega Sustenna | Paliperidone Palmitate | 116 | 14 |
| Ziprasidone Hcl | Ziprasidone Hcl | 113 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 110 | 24 |
| Lurasidone Hcl | Lurasidone Hcl | 102 | 13 |
| Oxcarbazepine | Oxcarbazepine | 101 | 14 |
| Temazepam | Temazepam | 101 | 11 |
| Caplyta | Lumateperone Tosylate | 97 | 19 |
| Aristada | Aripiprazole Lauroxil | 93 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 15 |
| Clonidine Hcl | Clonidine Hcl | 89 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 88 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 82 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 14 |
| Divalproex Sodium | Divalproex Sodium | 70 | suppressed |
| Paliperidone Er | Paliperidone | 70 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 69 | 12 |
| Methylphenidate Er | Methylphenidate Hcl | 67 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 62 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 62 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 62 | 12 |
| Lithium Carbonate | Lithium Carbonate | 60 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 59 | 12 |
| Doxepin Hcl | Doxepin Hcl | 54 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 53 | 11 |
| Zaleplon | Zaleplon | 52 | 11 |
| Vyvanse | Lisdexamfetamine Dimesylate | 51 | 12 |
| Abilify Maintena | Aripiprazole | 49 | suppressed |
| Haloperidol | Haloperidol | 49 | suppressed |
| Memantine Hcl | Memantine Hcl | 49 | 11 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 48 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 12 |
| Modafinil | Modafinil | 43 | suppressed |
| Eszopiclone | Eszopiclone | 41 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 38 | suppressed |
| Ingrezza | Valbenazine Tosylate | 33 | suppressed |
| Belsomra | Suvorexant | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Sunosi | Solriamfetol Hcl | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Perphenazine | Perphenazine | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Oxazepam | Oxazepam | 23 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 18 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Olanzapine Odt | Olanzapine | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Compro | Prochlorperazine | 12 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 12 | suppressed |
| Focalin Xr | Dexmethylphenidate Hcl | 12 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 12 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 12 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 12 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,369.21 · 170 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, Dyanavel XR, INVEGA SUSTENNA, Jornay PM, LOREEV XR, LUMRYZ, LYBALVI, Qelbree, REJOYN, REXULTI, Sunosi, WAKIX, XYWAV, ZURZUVAE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error